WO2006071896A3 - Epitope-based sars vaccine - Google Patents

Epitope-based sars vaccine Download PDF

Info

Publication number
WO2006071896A3
WO2006071896A3 PCT/US2005/047144 US2005047144W WO2006071896A3 WO 2006071896 A3 WO2006071896 A3 WO 2006071896A3 US 2005047144 W US2005047144 W US 2005047144W WO 2006071896 A3 WO2006071896 A3 WO 2006071896A3
Authority
WO
WIPO (PCT)
Prior art keywords
epitope
coronavirus
vaccine
sars
antibodies
Prior art date
Application number
PCT/US2005/047144
Other languages
French (fr)
Other versions
WO2006071896A2 (en
Inventor
Zhihong Guo
Xiaofen Zhong
Zufeng Guo
Huanghao Yang
Yong Xie
Original Assignee
Univ Hong Kong Science & Techn
Zhihong Guo
Xiaofen Zhong
Zufeng Guo
Huanghao Yang
Yong Xie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Hong Kong Science & Techn, Zhihong Guo, Xiaofen Zhong, Zufeng Guo, Huanghao Yang, Yong Xie filed Critical Univ Hong Kong Science & Techn
Publication of WO2006071896A2 publication Critical patent/WO2006071896A2/en
Publication of WO2006071896A3 publication Critical patent/WO2006071896A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

This invention provides a vaccine for the infectious severe acute respiratory syndrome (SARS), which comprises antigenic epitopes from the pathogenic coronavirus. The antigenic epitopes were determined from the complementary antibodies in the plasma of convalescent SARS patients through phage display epitope mapping. These immunodominants consit of short peptide fragments distributed on various viral proteins, which includes, the spike protein, the nucleocapsid protein, the replicase 1a, and the unknown proteins 3a and 9b. Complementary antibodies targeting the immunodominant site on the spike protein effectively neutralize the coronavirus in vitro. This epitope-based vaccine avoids potential immunopathologic effects found in vaccines for other human or animal diseases since the epitopes induced safe and benificial humoral antibodies in convalescent SARS patients.
PCT/US2005/047144 2004-12-23 2005-12-23 Epitope-based sars vaccine WO2006071896A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63818804P 2004-12-23 2004-12-23
US60/638,188 2004-12-23

Publications (2)

Publication Number Publication Date
WO2006071896A2 WO2006071896A2 (en) 2006-07-06
WO2006071896A3 true WO2006071896A3 (en) 2007-04-26

Family

ID=36615494

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/047144 WO2006071896A2 (en) 2004-12-23 2005-12-23 Epitope-based sars vaccine

Country Status (1)

Country Link
WO (1) WO2006071896A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010091763A1 (en) * 2009-02-16 2010-08-19 Atlas Antibodies Ab Rbm3 as a marker for malignant melanoma prognosis
WO2013132094A1 (en) * 2012-03-09 2013-09-12 Universitätsklinikum Heidelberg PEPTIDES BASED TARGETING OF THE PLATELET DERIVED GROWTH FACTOR RECEPTOR BETA (PDGFRβ) AND CD276
CN113248575B (en) * 2020-02-12 2022-11-01 北京科兴中维生物技术有限公司 Recombinant protein vaccine for SARS-CoV-2 and its preparing method
CN113248577B (en) * 2020-02-12 2022-10-21 北京科兴中维生物技术有限公司 Coronavirus vaccine using adenovirus as carrier and its preparing method
TW202208400A (en) * 2020-07-07 2022-03-01 英屬開曼群島商先知生物科技股份有限公司 Use of conserved peptide epitopes from sars-cov-2 for the development of a broad covid-19 vaccine
US20230285543A1 (en) * 2020-07-15 2023-09-14 University Of Southern California Peptide epitope vaccines for covid-19 and method of designing, making and using the same
CN112876542B (en) * 2021-02-08 2021-10-29 暨南大学 Novel epitope peptide of coronavirus T cell and application thereof
WO2022195120A1 (en) * 2021-03-19 2022-09-22 Charité - Universitätsmedizin Berlin Method for direct analysis of functional avidity of t cells
CN116284274A (en) * 2022-12-13 2023-06-23 中国兽医药品监察所 Recombinant erysipelothrix rhusiopathiae surface antigen SpaA protein and application thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004099240A2 (en) * 2003-05-09 2004-11-18 Adaltis Inc. Peptides and mixtures thereof for use in the detection of severe acute respiratory syndrome-associated coronavirus (sars)

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004099240A2 (en) * 2003-05-09 2004-11-18 Adaltis Inc. Peptides and mixtures thereof for use in the detection of severe acute respiratory syndrome-associated coronavirus (sars)

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GUO ET AL.: "SARS corona virus peptides recognized by antibodies in the sera of convalescent cases", VIROLOGY, vol. 324, no. 2, 1 July 2004 (2004-07-01), pages 251 - 256, XP004519178 *
LI ET AL.: "The epitope study on the SARS-CoV Nucleocapsid Protein", GENOMICS, PROTEOMICS, AND BIOINFORMATICS, vol. 1, no. 3, August 2003 (2003-08-01), pages 198 - 206, XP002342345 *
SCHULTES ET AL.: "Using antibodies in tumour immunotherapy", EXPERT OPINION IN BIOLOGICAL THERAPY, vol. 4, no. 8, 2004, pages 1265 - 1284, XP008078858 *

Also Published As

Publication number Publication date
WO2006071896A2 (en) 2006-07-06

Similar Documents

Publication Publication Date Title
WO2006071896A3 (en) Epitope-based sars vaccine
Coleman et al. MERS-CoV spike nanoparticles protect mice from MERS-CoV infection
Moser et al. Influenza virosomes as a vaccine adjuvant and carrier system
MXPA05009580A (en) Influenza virus vaccine.
TWI737584B (en) Hand, foot, and mouth vaccines and methods of manufacture and use thereof
WO2004112831A3 (en) High titer recombinant influenza viruses for vaccines and gene therapy
HUP0302643A2 (en) Vaccine
JP2009537143A5 (en)
DE60110822D1 (en) PREPARING FOR IMMUNIZING AGAINST THE AIDS VIRUS
WO2007103048A3 (en) Tlr agonist (flagellin)/cd40 agonist/antigen protein and dna conjugates and use thereof for inducing synergistic enhancement in immunity
JP2004527264A5 (en)
ATE542829T1 (en) VACCINE
DE602005025342D1 (en) VACCINE COMPOSITIONS WITH VIRUSOMES AND A SAPONIN ADJUVANS
IL150602A (en) Proteosome influenza vaccine, method for preparing such and use thereof
PT1409692E (en) Novel peptides of the respiratory syncytial virus (rsv) g protein and their use in a vaccine
WO2006115843A3 (en) Nipah virus vaccines
WO2002074795A3 (en) Oligomeric complexes of chimeric proteins with enhanced immunogenic potential
AU2003246373A1 (en) Recombinant measles viruses expressing epitopes pf antigens of rna viruses and use of the recombinant viruses for the preparation of vaccine compositions
WO2008054535A3 (en) Novel influenza m2 vaccines
WO2005081716A3 (en) DNA VACCINES TARGETING ANTIGENS OF THE SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS (SARS-CoV)
CY1110744T1 (en) Immunosuppressive combination for prophylactic and therapeutic treatment of US C
WO2007098718A8 (en) Chimeric vaccine antigens against the avian influenza virus
Kong et al. Modulation of the immune response to the severe acute respiratory syndrome spike glycoprotein by gene-based and inactivated virus immunization
WO2006076587A3 (en) Peptides for delivery of mucosal vaccines
WO2006045532A3 (en) Virosome particles comprising antigens from influenza virus and hepatitis b virus

Legal Events

Date Code Title Description
DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 05857228

Country of ref document: EP

Kind code of ref document: A2